Multiple Sclerosis Agents: Disease-Modifying and Symptomatic Therapies

Multiple sclerosis is a chronic autoimmune demyelinating disorder of the central nervous system that typically presents between ages 20-40, with higher prevalence in women and Northern European/North American populations. Current therapeutic approaches include disease-modifying immunomodulatory agents (interferons, glatiramer acetate, monoclonal antibodies, fumarates, and others) and symptomatic treatments to manage disease progression and disability.